MERSANA THERAPEUTICS INC. - COMMON STOCK

Mersana Therapeutics Announces 2022 Strategic Priorities and Milestones

07 Jan 2022 08:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

05 Jan 2022 08:00:02 By Nasdaq GlobeNewswire

Mersana Therapeutics Named to 2021 List of Top Places to Work in Massachusetts by The Boston Globe

02 Dec 2021 08:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics to Participate in the Upcoming 4th Annual Evercore ISI HealthCONx Conference

23 Nov 2021 08:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics to Present at the Upcoming Stifel 2021 Virtual Healthcare Conference

10 Nov 2021 08:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update

09 Nov 2021 06:00:00 By Nasdaq GlobeNewswire

Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2021 Financial Results and Business Updates

02 Nov 2021 08:00:02 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

27 Oct 2021 16:05:00 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Appointment of Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program Leadership

25 Oct 2021 08:00:00 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Target and Presents New Preclinical Data for XMT-2056, First Immunosynthen STING-Agonist ADC, at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

07 Oct 2021 16:05:00 By Nasdaq GlobeNewswire

Mersana Therapeutics to Announce Target and Present New Preclinical Data for XMT-2056 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

30 Sep 2021 08:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics to Present at Upcoming Investor Conferences

07 Sep 2021 08:00:03 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

18 Aug 2021 16:05:00 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Appointment of Tushar Misra, Ph.D., as Chief Manufacturing Officer

16 Aug 2021 08:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update

06 Aug 2021 06:00:00 By Nasdaq GlobeNewswire

Mersana Therapeutics to Present at the 12th Annual Wedbush PacGrow Healthcare Conference

04 Aug 2021 08:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2021 Financial Results and Business Updates

30 Jul 2021 08:00:00 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Initiation of the UPGRADE Phase 1 Platinum Combination Cohort for UpRi in Platinum-Sensitive Ovarian Cancer

28 Jul 2021 08:00:02 By Nasdaq GlobeNewswire

Mersana Therapeutics to Present at Jefferies Virtual Healthcare Conference

26 May 2021 08:00:02 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update

10 May 2021 16:01:00 By Nasdaq GlobeNewswire